NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

美國新型冠狀病毒 (COVID-19) 疫苗和治療藥物的後續行動 - 市場洞察和趨勢(2021 年上半年)

US COVID-19 Vaccines and Therapeutics Tracker-Market Insights and Trends, H1 2021

出版商 Frost & Sullivan 商品編碼 1006498
出版日期 內容資訊 英文 53 Pages
商品交期: 最快1-2個工作天內
價格
美國新型冠狀病毒 (COVID-19) 疫苗和治療藥物的後續行動 - 市場洞察和趨勢(2021 年上半年) US COVID-19 Vaccines and Therapeutics Tracker-Market Insights and Trends, H1 2021
出版日期: 2021年04月30日內容資訊: 英文 53 Pages
簡介

截至 2021 年 3 月 31 日,美國食品藥品監督管理局 (FDA) 已授予Pfizer□BioNTech、Moderna、Johnson & Johnson 生產的三種疫苗的緊急使用授權。 Novavax 和AstraZeneca生產的候選疫苗預計將於 2021 年第二季度獲得批准。

在本報告中,我們將跟進美國新型冠狀病毒(COVID-19)疫苗和治療劑,分析主要疫苗和治療劑的增長機會、研發情況、供應鏈趨勢和疫苗接種發展。總結趨勢等。

目錄

戰略建議

  • 增長機會推動增長管道引擎
  • 為什麼增長變得更加困難
  • 戰略要務 8
  • 三大戰略建議的影響

執行摘要

  • 美國主要後續指標(2021 年上半年)
  • 執行摘要

增長機會分析

  • 分析範圍

研發情況:主要疫苗

  • 管道分析
  • 緊急使用授權 (EUA) 疫苗
  • 與主要製造交易合作,以供應美國批准的疫苗
  • 第三期試驗中的主要候選疫苗

研發情況:主要治療藥物

  • 目前的補救措施
  • 第三期試驗中的小分子療法
  • 單克隆抗體處於第三期試驗階段

供應鏈管理:從工廠到疫苗接種現場

  • 新型冠狀病毒 (COVID-19) 疫苗製造供應鏈
  • 新型冠狀病毒 (COVID-19) 疫苗供應鏈:美國的主要利益相關者
  • 從工廠到接種現場的供應鏈
  • 疫苗分發框架
  • 物流商:使用冷鏈到接種現場
  • 物流供應商:Operation Warp Speed Logistics Partners 的主要活動
  • 中央分發中心:McKesson 在疫苗分發中的作用
  • 補充供應包:各種新型冠狀病毒(COVID-19)疫苗的要求
  • 擴大注射器和針頭製造規模以實現疫苗接種目標

美國新型冠狀病毒(COVID-19) 疫苗:接種快照

  • 按疫苗類型
  • 管理位置
  • 加強私營公司的分銷網絡
  • 主要州介紹
  • 成功案例介紹

新型冠狀病毒 (COVID-19) 流行期

  • 新型冠狀病毒 (COVID-19) 可能成為地方病
  • 新型冠狀病毒 (COVID-19) 疫苗接種的未來:季節性引入的可能性

增長機會領域

  • 增長機會 1:用於新興病毒變體和未來傳染病爆發的不可知疫苗平台技術
  • 主要公司:開發下一代 COVID-19 疫苗
  • 增長機會 2:提供注射器和乾冰以進行有效的大規模免疫
  • 展品清單
  • 免責聲明
目錄
Product Code: K613-52

Agnostic Vaccine Platform Technology Enhancing Future Growth Potential of Participants in the Value Chain

This study by Frost & Sullivan's Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. The US response to the pandemic has been disorganized and made worse with the politicization of vaccine approval and distribution, creating distrust and delaying the country's vaccination program. Each state in the US has its own vaccination strategy and as such, state health department websites are critical sources of information on when, where, and how to get vaccines.

As of 31 March 2021, the US Food & Drug Administration granted Emergency Use Authorization to three vaccines manufactured respectively by Pfizer and BioNTech, Moderna, and Johnson & Johnson. Novavax and AstraZeneca vaccines are two other leading vaccine candidates expected to be approved for use in Q2 2021. Apart from vaccines, drugs are likely to play a critical role in treating individuals not responding to vaccines, not receiving vaccines, and who still contracted the virus despite vaccination.

Maintaining vaccine integrity through all stages of the supply chain requires never-before-seen levels of monitoring and coordination among stakeholders. Partnerships between input supply firms and distributors are as critical as collaborations between vaccine sponsors and contract manufacturers to scale up production for mass immunization.

Key topics covered in the study include:

  • Key COVID-19 vaccines and therapeutics analysis
  • COVID-19 vaccines supply chain and distribution analysis
  • Snapshot of the US vaccination strategy
  • Prospective analysis of COVID-19 becoming endemic

Table of Contents

Strategic Imperatives

  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on the US COVID-19 Vaccines and Therapeutics Market

Executive Summary

  • H1 2021 US Key Tracking Metrics
  • Executive Summary
  • Executive Summary (continued)

Growth Opportunity Analysis, US COVID-19 Vaccines and Therapeutics Tracker

  • Scope of Analysis

COVID-19 R&D Landscape, Key Vaccines

  • COVID-19 Vaccines Snapshot-Pipeline Analysis
  • COVID-19 Vaccines Snapshot-Vaccines Granted EUA
  • COVID-19 Vaccines Snapshot-Key Manufacturing Deals and Partnerships for the US Supply of Approved Vaccines
  • COVID-19 Vaccines Snapshot-Key Vaccine Candidates in Phase III

COVID-19 R&D Landscape, Key Therapeutics

  • COVID-19 Therapeutics Snapshot-Current Global Treatments
  • COVID-19 Therapeutics Snapshot-Key Small Molecules in Phase III
  • COVID-19 Therapeutics Snapshot-Key mAbs in Phase III

COVID-19 Vaccines Supply Chain Management, from Factory to the Point of Vaccination

  • COVID-19 Vaccines Manufacturing Supply Chain-Stages and Inputs
  • COVID-19 Vaccines Supply Chain-US Key Stakeholders
  • COVID-19 Vaccines Supply Chain from Factory to the Point of Use
  • US COVID-19 Vaccines Distribution Framework
  • Logistics Providers-Maintaining the Cold Chain to the Point of Use
  • Logistics Providers-Key Activities of Operation Warp Speed's Logistics Partners
  • Central Distribution Hub-McKesson's Role in Vaccines Distribution
  • Ancillary Supply Kits-Requisites for Different COVID-19 Vaccines
  • Scaling Up Syringes and Needles Manufacturing to Meet Vaccination Targets

US COVID-19 Vaccination Snapshot

  • US COVID-19 Vaccination Snapshot-By Vaccine Type
  • US COVID-19 Vaccination Snapshot-Administration Sites
  • US COVID-19 Vaccines Distribution Sites-Private Companies Fortifying Distribution Networks
  • US COVID-19 Vaccination Snapshot-Rollout in Key States
  • US COVID-19 Vaccination Snapshot-Successful Rollout Examples

COVID-19 Endemic Phase, Prospective Analysis

  • Possible Factors of COVID-19 Becoming Endemic
  • Future of COVID-19 Vaccination-Seasonal Rollout Possibility

Growth Opportunity Universe, US COVID-19 Vaccines and Therapeutics Tracker

  • Growth Opportunity 1-Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021
  • Growth Opportunity 1-Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021 (continued)
  • Key Companies-Developing Next-generation COVID-19 Vaccines
  • Growth Opportunity 2-Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021
  • Growth Opportunity 2-Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021 (continued)
  • List of Exhibits
  • List of Exhibits (continued)
  • Legal Disclaimer